Greg Jones

Company: Pfizer

Job title: Principal Scientist

Seminars:

Targeting PDAC Through a First-in-Class DOCK5 Degrader to Inhibit the RAS Pathway 2:30 pm

Showcasing the discovery of a highly selective and potent DOCK5 degrader to target a top dependency of KRAS mt Pancreatic cancer cell lines Displaying how targeted protein degradation of DOCK5 demonstrates anti-tumor activity in KRAS mt PDAC models in vitro and in vivo offering a promising new therapy Exploring how combining a DOCK5deg with direct…Read more

day: Day One Track A PM